Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT-UC: mirikizumab with tirzepatide in adults with ulcerative colitis and obesity or overweight
NL-OMON61084Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis, obesity and Overweight comparing Mirikizumab + tirzepatide with Mirikizumab + placebo (2 arms). Primary endpoint: Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction. Started Sep 2025; status: recruiting.
02
Drugs
mirikizumabtirzepatide
03
Conditions
autoimmune colitisobesityOverweight
Beyond the preview
Go deeper on NL-OMON61084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61084.